| Drug Name | Janus kinase inhibitors |
|---|---|
| Drug Class | |
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) | |
| Risk |
Minimize the risks of serious side effects (cardiovascularevents, blood clots, cancer, serious infections and mortality) |
| safety communication |
|